

ASCENDIS HEALTH

MEDIA RELEASE

25 June 2021

ASCENDIS HEALTH TO SELL FARMALIDER STAKE FOR R84 MILLION AND GAIN EXCLUSIVE RIGHTS TO PRODUCT PORTFOLIO FOR 25 AFRICAN COUNTRIES

Johannesburg – Ascendis Health has today announced the planned disposal of its 49% shareholding in Spanish pharmaceutical company, Farmalider, for R84 million (€4.98 million).

The shareholding will be acquired by Spanish investment company MMC International Health Holding.

The disposal forms part of the Ascendis Health recapitalisation announced in May 2021, aimed at reducing the group's unsustainably high debt levels.

The Farmalider shareholding was to be transferred to senior lenders Blantyre Capital and L1 Health in exchange for debt, and these lenders have instead agreed to the separate disposal of the asset in an accelerated sale process. The net proceeds from this disposal will be applied to reducing Ascendis Health's debt.

Farmalider is headquartered in Madrid and develops, licences and supplies mainly generic and over-the-counter products to a range of multinational companies. Farmalider was the first offshore acquisition made by Ascendis Health back in 2015.

Ascendis Health CEO Mark Sardi said that as part of the transaction, the Ascendis Pharma business in South Africa will gain indefinite and exclusive access to Farmalider's product portfolio for the 14 Southern African Development Community countries, including South Africa, and a further 11 African countries.

Farmalider's products target mainly pain relief, with key molecules consisting of combinations of paracetamol, ibuprofen and tramadol. Farmalider also competes in other therapeutic areas of cardiovascular, antibiotics, osteoporosis, anti-virals and anti-depressants.

“We believe this product pipeline of Farmalider will enhance the value of Ascendis Pharma’s business, once approval has been granted by the South African Health Products Regulatory Authority.”

Sardi said the sale of the Farmalider shareholding is the third disposal announced by Ascendis Health in the past six weeks. “In May we announced plans to sell Respiratory Care Africa, one of the businesses in our Medical Devices division, for R450 million, and also the Biosciences business for R85 million.”

He added that negotiations for the disposal of the company’s Animal Health business are at an advanced stage, with the sale expected to generate gross proceeds of R740 million to R790 million.

Ends

Issued by Tier 1 Investor Relations on behalf of Ascendis Health

For further information kindly contact:

Graeme Lillie, Tier 1 Investor Relations 082 468 1507